News | August 28, 2023
Gland Pharma receives 2 observations under 483 for Pashamylaram facility
The company is committed to address the observations and will submit its response to US FDA within the stipulated time
The company is committed to address the observations and will submit its response to US FDA within the stipulated time
Zinc Sulfate Injection is indicated in adult and paediatric patients as a source of zinc for parenteral nutrition
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Mizoram appoints Youth for Action as the Interfacing Agency for implementing the ABDM Microsite in Aizawl
Eris Lifesciences enters into term loan agreement with Citi Bank
Jupiter has filed its draft herring prospectus (DRHP) with the market regulator in May this year, to float its IPO
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
ABB India has secured an order from Reliance Life Sciences to deploy automation and control solutions for their new biosimilars and plasma proteins manufacturing facilities in Nashik, Maharashtra
Subscribe To Our Newsletter & Stay Updated
